

Toujeo[®] reduced the rate of severe low blood sugar events compared to some first generation long-acting insulins

VIENNA – February 14, 2018 – With the continued evolution in diabetes care and a growing understanding of today's insulin options, Sanofi is pleased to share new real-world study results which showed that Toujeo[®] (insulin glargine 300 Units/mL) significantly reduced the rate of severe low blood sugar (hypoglycemia) events compared to the long-acting insulins, insulin glargine 100 Units/mL (Lantus[®]) and insulin detemir. These data are being presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Vienna, Austria.¹


New findings from LIGHTNING, a large real-world comparative study involving more than 10,000 patients treated with long-acting insulins, found that Toujeo reduced the rate of severe low blood sugar events, defined by events related to an inpatient or emergency room visit for people with type 2 diabetes, by more than 60% compared to insulin glargine 100 Units/mL and insulin detemir. The data also showed that the rate of severe low blood sugar events was comparable between Toujeo and insulin degludec. The reduction of blood sugar levels were not compromised in any of the treatment arms. Further analyses are planned to correlate the findings with clinical and economic outcomes.

Severe hypoglycemia is a major issue for healthcare providers. Between 2007 and 2011, around 100,000 people per year visited emergency departments in the U.S. due to hypoglycemia. Severe hypoglycemia can represent a major burden for patients.²

The LIGHTNING study, previous randomized clinical trials and real-world analyses with Toujeo, including EDITION and DELIVER programs, together consistently demonstrate a significant reduction in hypoglycemia risk for patients with type 2 diabetes versus some first generation basal insulins. The lower risk of hypoglycemia versus insulin glargine 100 Units/mL has been confirmed in multiple clinical trials. Studies have also demonstrated the more stable profile of Toujeo versus insulin glargine 100 Units/mL, and the flatter profile with fewer within-day fluctuations of Toujeo versus insulin degludec.

About the LIGHTNING Study

The LIGHTNING study evaluated electronic medical records of 130,155 adult patients in the U.S. Optum-Humedica database who were treated with long-acting insulins. Using innovative statistical techniques, the study identified 10,458 adults with type 2 diabetes, with a majority of similar demographics and clinical characteristics, who switched from using any long-acting insulin to Toujeo, insulin glargine 100 Units/mL, insulin detemir or insulin degludec.



“Sanofi is committed to conducting ongoing research of our medicines to help healthcare professionals better understand not only their efficacy, but also important safety information such as the risk of hypoglycemia when compared to other treatment options,” said Antonio Tataranni MD, Senior Vice President & Head of Medical Affairs, Diabetes and Cardiovascular, at Sanofi. *“This study adds to a consistent body of evidence comparing Toujeo with long-acting insulins. They also strengthen our belief in using machine learning and big data to push the boundaries of real-world studies so healthcare professionals and payers can use the data to help inform their treatment decisions.”*

References

1. Meneghini L et al., “Hypoglycemia risk associated with basal insulin use in type 2 diabetes (T2DM): The Lightning study”, Abstract ATTD8-0420, 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD), February 14–17, 2018, Vienna, Austria.
2. Ward A et al., “Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012)”, J Med Econ. 2014 Mar;17(3):176-83. doi: 10.3111/13696998.2014.882843. Epub 2014 Jan 28.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Global Diabetes Communications

Serge Spierckel

Tel.: +33 (0) 6 75 71 61 24

serge.spierckel@sanofi.com

SANO.TJO.18.02.0046